delisting | GenomeWeb


The company has received a number of warnings from the Nasdaq over the past year for its failure to meet the exchange's $35 million market value and $1 minimum bid price requirements.

The suspension results from the firm's failure to comply with Nasdaq listing requirements covering stockholders' equity and market capitalization.

The reverse stock split was done in order for BG Medicine to remain listed on Nasdaq, which had warned the firm in September of possible delisting action.

The company's stock failed to meet the exchange's $1 minimum bid requirement.

The Australian firm regained compliance with a listing rule requiring a minimum $2.5 million in stockholder equity.

The company borrowed $2 million pursuant to an amendment to a $12 million credit agreement. It also said that it has until June 19 to meet certain listing requirements. 

The firm's shareholders will vote next month on the proposals, which are aimed at getting Nanosphere back in compliance with Nasdaq listing requirements.

NEW YORK (GenomeWeb News) – Nasdaq has notified BG Medicine that the company has not regained compliance with a listing requirement calling for at least $50 million in market value of its listed securities for continued listing on the exchange, BG Medicine said in a regulatory document.

NEW YORK (GenomeWeb News) – Warnex today announced it has completed the sale of its Analytical Services division to Neopharm Labs.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Pressure BioSciences has been delisted by the Nasdaq Stock market after failing to come into compliance with two requirements for continued listing.


In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.